Fair enough Golfyeti. But what apabetalone modified risk factors do you suggest overlap/compete with the SGLT2s? Those were first approved for glucose control prior to CVOTs. I can't tell if you are suggesting that you anticipate apabetalone to provide equal or superior glucose control vs. an SGLT2 inhibitor, or just comparing MACE reduction.
BearDownAZÂ
